Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Walgreens Boots Alliance Inc    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Walgreen Company : Walgreen April Same-Store Sales Fall Bigger-Than-Expected 6.4%

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 02:39pm CEST

Walgreen Co.'s (WAG) April same-store sales fell a bigger-than-expected 6.4%--marking the fourth straight month of declines--as the drug-store chain's loss of Express Scripts Holding Co.'s (ESRX) members continued to hamper results.

Analysts polled by Thomson Reuters expected April same-store sales to fall 5.1%.

A conflict between Walgreen and Express Scripts over new contract terms erupted publicly last June, and Walgreen said it wouldn't be part of the pharmacy-benefits manager's network when their deal expired in 2011. The benefit manager's clients now have to go elsewhere to fill prescriptions.

Total sales fell 3.7% to $5.78 billion last month.

April same-pharmacy sales decreased 8.9% and missed the analysts' projected 8.6% decline.

Total pharmacy sales fell 6.3%. Prescriptions filled at same-stores declined 7.8% in April, reflecting the loss of Express Scripts members, a lower incidence of flu and more generic drug introductions. Prescriptions processed by Express Scripts comprised 12.6% of Walgreen's prescriptions a year earlier.

In the front of the store, same-store sales slipped fell 2.2% last month, compared with the analysts' flat front-end same-store sales forecast.

Total front-end sales slipped 0.5%. Customer traffic at same-stores fell 3% and average basket size increased 0.8%.

Walgreen reported in March its fiscal second-quarter earnings fell 7.7% as its exit from Express Scripts's network and a mild cold and flu season offset a 0.8% pop in total sales.

Shares closed Wednesday at $34.15 and were inactive premarket. The stock has gained 3.3% since the beginning of the year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on WALGREENS BOOTS ALLIANCE I
04/22 WALGREENS BOOTS ALLIANCE : pays $9.8 million settlement over drug billing
04/20 WALGREENS BOOTS ALLIANCE : Declares Regular Quarterly Dividend
04/19 WALGREENS BOOTS ALLIANCE, INC. : Change in Directors or Principal Officers, Othe..
04/19 WALGREENS BOOTS ALLIANCE : José E. Almeida, Chairman and CEO of Baxter Internati..
04/18 WALGREENS : Healthcare Clinics to Offer Testing Services for Sexually Transmitte..
04/18 WALGREENS BOOTS ALLIANCE : Inspires 'Noses On' Across America to Support Third A..
04/17 WALGREENS : Inspires “Noses On” Across America to Support Third Annu..
04/14 WALGREENS BOOTS ALLIANCE : Expands Beauty Offering with Addition of NYX Professi..
04/13 WALGREENS : Expands Beauty Offering with Addition of NYX Professional Makeup Pro..
04/13 WALGREENS BOOTS ALLIANCE INC : Post Earnings Coverage as Walgreens' Quarterly Sa..
More news
Sector news : Drug Retailers - NEC
04/19DJCardinal Swoops In, Strikes Deal -- WSJ
04/18DJCARDINAL HEALTH : $6.1 Billion Deal for Some Medtronic Operations Raises Debt Co..
04/18DJCARDINAL HEALTH : $6.1 Billion Deal for Some Medtronic Operations Raises Debt Co..
03/08DJHealth Costs Get a Rethink -- WSJ
02/14DJEXPRESS SCRIPTS : Revenue Falls
More sector news : Drug Retailers - NEC
Advertisement
Financials ($)
Sales 2017 117 598 M
EBIT 2017 7 383 M
Net income 2017 4 539 M
Debt 2017 12 752 M
Yield 2017 1,80%
P/E ratio 2017 20,14
P/E ratio 2018 17,14
EV / Sales 2017 0,88x
EV / Sales 2018 0,81x
Capitalization 90 832 M
More Financials
Chart WALGREENS BOOTS ALLIANCE I
Duration : Period :
Walgreens Boots Alliance I Technical Analysis Chart | US9314221097 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 93,5 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefano Pessina Executive Vice Chairman & Chief Executive Officer
James A. Skinner Executive Chairman
Ornella Barra Co-Chief Operating Officer
Alexander W. Gourlay Co-Chief Operating Officer
George Rollo Fairweather Global Chief Financial Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
WALGREENS BOOTS ALLIAN..-0.07%90 832
WALGREENS BOOTS ALLIAN..1.53%90 832
CVS HEALTH CORP0.66%82 118
EXPRESS SCRIPTS HOLDIN..-3.39%39 897
MCKESSON CORPORATION-3.23%28 822
CARDINAL HEALTH INC0.74%22 870
More Results